CTIS2023-504338-24-00进行中（未招募）1 期
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF DOSE-TITRATED PLS240 IN THE TREATMENT OF SECONDARY HYPERPARATHYROIDISM IN INDIVIDUALS WITH END STAGE KIDNEY DISEASE ON HEMODIALYSIS (PATH-1) WITH AN OPEN-LABEL EXTENSION - PP3002
Pathalys Pharma Inc.0 个研究点目标入组 375 人开始时间: 2023年5月31日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 375
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Aged 18 - 80 years at time of informed consent., Pre-dialysis central laboratory iPTH must be =400 pg/mL on at least two assessments performed at 2 visits, at least 1 week apart, during the Active Screening period. iPTH may be tested up to 4 times during the Active Screening period., Voluntarily given written informed consent to participate in this study, Agrees to not participate in another study of an investigational agent during the study, To be eligible for inclusion into the Open-Label Extension Phase of the study, participants must fulfill the additional following criteria at the time of entry into the Open-Label Extension Phase: Have successfully completed the course of treatment and final safety follow-up visit of the Double-Blind Phase, Voluntarily given written informed consent to participate in the Open-Label Extension Phase of the study, Prescribed hemodialysis for 3 times per week, Continue to meet Inclusion Criteria 9, 10, and 12, Prescribed hemodialysis for 3 times per week and on therapy for at least 3 months and has a delivered Kt/V=1.2 within 4 weeks prior to signing the ICF., Pre-dialysis central laboratory screening iPTH must be =450 pg/mL on two measurements performed at 2 visits at least 1 week apart. Only one (1) repeat iPTH is allowed and must be performed at least a week after the previous iPTH., Pre-dialysis central laboratory cCa must be =8.3 mg/dL on at least one assessment performed during the Active Screening period. cCa may be tested up to 3 times during the Active Screening period. 5.Dialysate calcium concentration =2.5 mEq/L (1.25 mmol/L) and stable for at least 4 weeks prior to signing the ICF., Dialysate calcium concentration =2.5 mEq/L (1.25 mmol/L) and stable for at least 4 weeks prior to signing the ICF., Participants receiving active Vitamin D sterols (e.g., doxercalciferol or calcitriol) to manage SHPT must be on a stable dose (e.g., maximum dose change =50%), in the opinion of the investigator or sub-investigator, within the 2 months prior to signing the ICF, remain stable, as defined as no increase in dose, through the screening period, and be expected to maintain a stable dose, as defined as no increase in dose, for the duration of the study., Participants receiving phosphate binders must be on a stable dose (e.g., maximum dose change =50%), in the opinion of the investigator or sub-investigator, within the 2 months prior to signing the ICF, remain stable through the screening period, and be expected to maintain stable dose for the duration of the study., Participants receiving calcium supplements must be on a stable dose (e.g., maximum dose change =50%), in the opinion of the investigator or sub-investigator, within the 2 months prior to signing the ICF and remain stable through the screening period., Female participants who are post-menopausal (‘post-menopausal’ women have had no menses for the previous year and are over the age of 50 years), or surgically sterilized, or have a medical condition that prevents pregnancy, or commit to remain abstinent during the study and for 2 weeks after the last dose of the investigational product (IP), or are willing to use highly effective contraception (see Section 8.8) during the study and for 2 weeks after the last dose of IP. Women of child-bearing potential must have a negative serum pregnancy test during the screening period. 10.Male participants who are willing to use highly effective contraception (see Section 8.8) when sexually active and will no
排除标准
- •Diagnosis of primary hyperparathyroidism, Poorly controlled diabetes mellitus, in the judgment of the investigator or sub-investigator, Poorly controlled hypertension (defined as post-dialysis [seated if available] systolic pressure >180 mmHg and/or diastolic pressure >110 mmHg) at 2 or more dialysis sessions during the 2 weeks prior to signing the ICF, Pre-dialysis central laboratory Active Screening iPTH >1500 pg/mL on two or more occasions. iPTH may be tested up to 4 times during the Active Screening period., Currently enrolled in, or have not yet completed at least 30 days before Baseline/Day 1 other invasive investigational device or investigational drug trials, or are receiving other investigational agents (experimental dialysis machines are acceptable), History of symptomatic ventricular dysrhythmias or Torsade de Pointes., History of or family history of long QT syndrome, QTcF >500msec on screening ECG, Pregnant or breast feeding, Prior exposure or hypersensitivity to PLS240 or any of its components, Current, recent, or suspected infection with SARS-CoV-2/COVID-19 within 4 weeks prior to signing the ICF, Clinically significant abnormalities on screening laboratory tests (may repeat abnormal laboratory tests as defined in Ssection 7.4.1) according to the Investigator including but not limited to the following: a. Serum albumin =3.0 g/dL b. Serum magnesium <1.5 mg/dL c. Serum P >8.0 mg/dL d. Hemoglobin <8.5 g/dL e. Platelet count <100,000 x106/L f. Serum transaminase (alanine transaminase [ALT] or Serum glutamic pyruvic transaminase [SGPT], aspartate aminotransferase [AST] or serum glutamic oxaloacetic transaminase [SGOT]) = 2.5 times the upper limit of normal (ULN) during Active Screening, In the opinion of the investigator any disorder that would interfere with understanding and giving informed consent, or compliance with protocol requirements, In the opinion of the investigator continuation into the Open-Label Extension Phase is not considered safe and/or feasible, Continues to meet Exclusion Criterion #5, iPTH >1500 pg/mL at the final assessment during the EAP and at the Follow-up visit of the Double-Blind Phase, History of parathyroid intervention including parathyroidectomy (PTx) and/or percutaneous ethanol injection therapy (PEIT) within 26 weeks before screening., Treatment with any prohibited medication as defined in protocol Section 8.3.1., Anticipated or scheduled parathyroidectomy during the study period., Planned living-related or living-unrelated kidney transplant during the study period., Change in mode of dialysis (e.g., from hemodialysis to hemodiafiltration, peritoneal dialysis to hemodialysis, at home to in center dialysis), dialysate Ca concentration, or prescribed dialysis treatment time within 4 weeks before signing the ICF, Noncompliant with hemodialysis (i.e., missing more than 3 dialysis sessions within 8 weeks prior to signing the ICF, unless absence is due to hospitalization), Diagnosed with an unstable medical condition, defined as having been hospitalized, other than for dialysis vascular access intervention, within 30 days prior to signing the ICF or otherwise unstable in the judgment of the investigator, History of malignancy within the last 2 years prior to signing the ICF (except squamous or basal cell skin cancers, or cervical carcinoma in situ)., Recent history (within 4 weeks prior to signing the ICF) of angina pectoris with symptoms that occur at rest or minimal activity. Chest pain on dial
研究者
相似试验
尚未招募
3 期
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DAZODALIBEP IN PARTICIPANTS WITH SJÖGREN’S SYNDROME WITH MODERATE-TO-SEVERE SYSTEMIC DISEASE ACTIVITYM350 Sicca syndrome [Sjogren]Sicca syndrome [Sjogren]M350PER-050-23Horizon Therapeutics Ireland DAC
进行中（未招募）
1 期
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF THE ANALGESIC EFFICACY AND SAFETY OF THE SUBCUTANEOUS ADMINISTRATION OF TANEZUMAB (PF-04383119) IN SUBJECTS WITH CANCER PAIN PREDOMINANTLY DUE TO BONE METASTASIS RECEIVING BACKGROUND OPIOID THERAPYEUCTR2013-002223-42-HUPfizer Inc, 235 East 42nd Street, New York, NY 10017176
进行中（未招募）
1 期
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF THE ANALGESIC EFFICACY AND SAFETY OF THE SUBCUTANEOUS ADMINISTRATION OF TANEZUMAB (PF-04383119) IN SUBJECTS WITH CANCER PAIN PREDOMINANTLY DUE TO BONE METASTASIS RECEIVING BACKGROUND OPIOID THERAPYMetastatic Bone PainMedDRA version: 21.1Level: LLTClassification code 10049038Term: Metastatic bone painSystem Organ Class: 100000004864EUCTR2013-002223-42-CZPfizer Inc, 235 East 42nd Street, New York, NY 10017155
进行中（未招募）
1 期
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF THE ANALGESIC EFFICACY AND SAFETY OF THE SUBCUTANEOUS ADMINISTRATION OF TANEZUMAB IN SUBJECTS WITH OSTEOARTHRITIS OF THE HIP OR KNEEOsteoarthritis of the hip or kneeMedDRA version: 20.0Level: LLTClassification code 10023476Term: Knee osteoarthritisSystem Organ Class: 100000004859MedDRA version: 20.0Level: LLTClassification code 10020108Term: Hips osteoarthritisSystem Organ Class: 100000004859EUCTR2013-004508-21-DEPfizer Inc, 235 East 42nd Street, New York, NY 10017849
尚未招募
不适用
SAPPHIRE - A STUDY TO SEE IF PIMODIVIR IN COMBINATION WITH STANDARD OF CARE TREATMENT IS USEFUL AND SAFE IN THE TREATMENT OF ADOLESCENT, ADULT AND ELDERLY HOSPITALIZED PATIENTS WITH INFLUENZA A INFECTION.PER-016-18Janssen Research & Develoment, LLC,